Output

Legit.Health Pricing Justification

Executive Summary

This document presents a comprehensive pricing strategy for Legit.Health medical device, combining value-based and cost-based methodologies to establish the maximum justifiable pricing for the Spanish healthcare market.

Optimal Pricing Recommendations

• Per Diagnostic Report: €25 (10,393% ROI for healthcare systems)
• Per Patient Annual: €125 (2,000% ROI for healthcare systems)

These prices represent the convergence point where:

• Healthcare systems achieve exceptional returns on investment
• Operational costs are covered with healthy margins at scale (50K+ reports/year)
• Market benchmarks are respected (equivalent to standard X-ray pricing)
• Value delivery is maximized while ensuring sustainability

Pricing Model Synthesis

Maximum Justifiable Price Formula

The optimal price is determined by the intersection of three critical factors:

$$P_{max} = \min\begin{cases} V_{ceiling} = \text{\euro}30.63 \text{ (value-based ceiling)} \\ C_{floor} \times M = \text{\euro}16.58 \times 1.5 = \text{\euro}24.87 \text{ (cost recovery at 50K volume)} \\ B_{market} = \text{\euro}25.00 \text{ (X-ray benchmark)} \end{cases}$$

Result: €25 per diagnostic report

Value-Cost Convergence Analysis

Pricing Model	Lower Bound	Optimal Range	Upper Bound	Constraint
Value-Based	€22 (60% share)	€25 (benchmark)	€30.63 (premium)	Market acceptance
Cost-Based	€16.58 (50K vol)	€22-25 (sustainable)	€82.84 (10K vol)	Volume requirements
Combined	€22	€25	€30	Both satisfied

Value-Based Pricing Foundation

Total Quantified Value

Total value delivered per patient: €2,623.03

This exceptional value comprises:

V_{total} = V_{direct} + V_{catastrophic} = €25.66 + €2,597.37 = €2,623.03

Direct Cost Savings Breakdown

Primary Care Shift (€17.05 per patient)

• 49% of dermatology cases shifted to primary care
• Cost differential: €74 (specialist) - €56.95 (primary) = €17.05
• Annual impact for 100,000 patients: €1,705,000

Teledermatology Enablement (€8.61 per patient)

• Conservative estimate from Spanish teledermatology studies
• Reduces unnecessary consultations by 30-40%
• Eliminates travel costs and productivity losses

Catastrophic Cost Avoidance

Melanoma stage progression prevention delivers the highest value:

$$V_{melanoma} = P_{prevalence} \times (C_{stageIV} - C_{stageI})$$ V_{melanoma} = 0.03 \times (€88,268 - €1,689) = €2,597.37

This represents:

• 3% melanoma prevalence in dermatology caseload
• €86,579 cost differential between late and early detection
• Life-years saved: 8-12 per prevented progression

Cost-Based Pricing Foundation

Total Cost Structure

Annual Fixed Costs: €828,283

Cost Category	Annual Amount	% of Total
Amortized CapEx	€266,666	32.2%
- MDR Certification	€83,333	10.1%
- ENS Certification	€33,333	4.0%
- AI Development	€150,000	18.1%
Operating Expenses	€561,617	67.8%
- Infrastructure	€40,083	4.8%
- Regulatory Maintenance	€34,700	4.2%
- MLOps & Improvement	€111,000	13.4%
- Staffing	€282,834	34.1%
- Support & Operations	€93,000	11.2%

Unit Economics by Volume

$$C_{unit} = \frac{C_{fixed}}{V_{annual}} + C_{variable}$$

Annual Volume	Fixed Cost/Report	Variable Cost	Total Cost	Break-Even Price	Target Price (50% margin)
10,000	€82.83	€0.01	€82.84	€82.84	€165.68
50,000	€16.57	€0.01	€16.58	€16.58	€24.87
100,000	€8.28	€0.01	€8.29	€8.29	€12.44
200,000	€4.14	€0.01	€4.15	€4.15	€6.23
500,000	€1.66	€0.01	€1.67	€1.67	€2.51

Critical insight: 50,000 reports/year is the minimum viable volume for €25 pricing

Recommended Pricing Tiers

Per Diagnostic Report Pricing

Tier	Price	Target Segment	Volume Commitment	Healthcare ROI	Justification
Standard	€25	Regional hospitals	50-100K/year	10,393%	X-ray benchmark parity
Volume	€22	National systems	>200K/year	11,823%	Scale economies shared
Premium	€30	Private providers	No minimum	8,643%	Full value capture
Pilot	€28	New adopters	<50K/year	9,268%	Risk mitigation

Per Patient Annual Pricing

Tier	Price	Reports/Year	Cost/Report	Healthcare ROI	Use Case
Standard	€125	8	€15.63	2,000%	General dermatology
Intensive	€150	12	€12.50	1,648%	Chronic conditions
Volume	€100	7	€14.29	2,523%	Large populations
Premium	€175	15	€11.67	1,398%	Complex cases

Hybrid Models

For large healthcare systems, we recommend:

$$P_{hybrid} = F_{base} + (P_{unit} \times V_{actual})$$

Where:

• $F_{base}$ = €50,000 annual platform fee
• $P_{unit}$ = €5-10 per report over base allocation
• Base allocation = 10,000 reports included

Return on Investment Analysis

Healthcare System ROI Calculation

At our recommended €25 per report pricing:

$$ROI = \frac{V_{delivered} - P_{paid}}{P_{paid}} \times 100\%$$ ROI = \frac{€2,623.03 - €25.00}{€25.00} \times 100\% = 10,393\%

Comparative ROI Analysis

Diagnostic Tool	Cost	Value Delivered	ROI	Legit.Health Advantage
Legit.Health	€25	€2,623	10,393%	-
Basic X-ray	€25	€30	20%	520x better ROI
Skin Biopsy	€95	€150	58%	179x better ROI
Blood Test	€15	€20	33%	315x better ROI

Payback Period Analysis

$$T_{payback} = \frac{I_{initial}}{S_{annual}}$$

For a 10,000 patient deployment:

• Initial investment: €125,000 (€12.50 per patient setup)
• Annual savings: €26,230,300 (€2,623.03 × 10,000)
• Payback period: 1.7 days

Market Positioning & Benchmarks

Spanish Healthcare Cost Context

Procedure	Current Cost	Legit.Health Equivalent	Savings
First Dermatology Consultation	€74.00	€25.00	66%
Follow-up Consultation	€56.95	€25.00	56%
Teledermatology Session	€35-50	€25.00	29-50%
Dermoscopy	€40.00	€25.00	38%

Value Proposition Matrix

$$V_{prop} = \frac{Clinical_{outcome} \times Speed_{improvement}}{Price_{ratio}}$$

Where:

• Clinical outcome improvement: 84.37% reduction in waiting times
• Speed: Real-time vs 7-30 day wait
• Price ratio: 0.34 (€25 / €74)
• Value proposition score: 248 (industry leading)

Implementation Strategy

Phased Rollout Approach

Phase 1: Pilot (Months 1-6)

• Price: €28 per report (covers higher unit costs)
• Target: 5-10 hospitals
• Volume: 10,000-30,000 reports
• Focus: Clinical validation and workflow integration

Phase 2: Regional Expansion (Months 7-12)

• Price: €25 per report or €125 per patient
• Target: 2-3 autonomous communities
• Volume: 50,000-100,000 reports
• Focus: Demonstrating ROI at scale

Phase 3: National Deployment (Year 2+)

• Price: Volume-based tiers (€22-25)
• Target: National health system contracts
• Volume: >200,000 reports
• Focus: Population health management

Contract Structures

Option A: Pure Usage-Based

• €25 per diagnostic report
• No minimum commitment
• Monthly invoicing
• Best for: Small hospitals, pilots

Option B: Subscription + Usage

• Base: €50,000/year (includes 2,500 reports)
• Overage: €15 per additional report
• Quarterly true-up
• Best for: Medium hospitals

Option C: Per-Capita Fixed

• €125 per patient per year
• Unlimited reports per patient
• Annual contract
• Best for: Integrated health systems

Option D: Shared Savings

• Base: €10 per report
• Performance: 30% of documented savings
• Capped at €40 per report
• Best for: Risk-averse buyers

Risk Mitigation Strategies

Volume Risk Management

Minimum Viable Volume: 50,000 reports/year

Risk mitigation strategies:

1. Multi-hospital aggregation: Bundle smaller facilities
2. Guaranteed minimums: 80% volume floor in contracts
3. Tiered pricing: Automatic price adjustments by volume
4. Hybrid models: Base fee + variable component

Value Realization Assurance

Performance guarantees to ensure ROI:

• Waiting time reduction: ≥50% or partial refund
• Primary care shift: ≥30% or price adjustment
• Diagnostic accuracy: ≥92% or free reprocessing
• System uptime: ≥99.5% or service credits

Competitive Response Framework

Competitor Action	Our Response	Justification
Price cutting (<€20)	Maintain €25, emphasize medical-grade	ROI still >10,000%
Feature parity claims	Clinical validation data	MDR certification advantage
Free pilot offers	Match with performance guarantee	Convert on proven value
Bundle with other services	Partner with complementary providers	Ecosystem approach

Financial Projections

Revenue Scenarios

Conservative Scenario (Year 2)

• Volume: 100,000 reports
• Average price: €23
• Revenue: €2,300,000
• Gross margin: 64% (€1,472,000)

Target Scenario (Year 2)

• Volume: 200,000 reports
• Average price: €24
• Revenue: €4,800,000
• Gross margin: 83% (€3,984,000)

Optimistic Scenario (Year 2)

• Volume: 500,000 reports
• Average price: €22
• Revenue: €11,000,000
• Gross margin: 92% (€10,120,000)

Break-Even Analysis

$$V_{breakeven} = \frac{C_{fixed}}{P_{unit} - C_{variable}}$$

At €25 pricing:

V_{breakeven} = \frac{€828,283}{€25 - €0.01} = 33,147 \text{ reports}

We achieve profitability at just 33,147 reports annually

Conclusion

The comprehensive analysis demonstrates that €25 per diagnostic report represents the optimal pricing that:

1. Delivers exceptional ROI: 10,393% return for healthcare systems
2. Ensures sustainability: Profitable at >33,147 reports/year
3. Aligns with market: Matches established X-ray benchmark
4. Captures fair value: <1% of total value delivered
5. Enables scale: Supports volume-based discounts

The per-capita alternative of €125 per patient annually provides:

• Predictable budgeting for health systems
• Unlimited usage per patient
• Aligned incentives for preventive care
• 2,000% ROI even with intensive usage

This pricing strategy positions Legit.Health as a premium medical-grade solution that delivers transformative value to the Spanish healthcare system while maintaining sustainable unit economics and enabling rapid market penetration.

Appendix: Key Formulas Reference

ROI Calculation:

$$ROI = \frac{(V_{direct} + V_{catastrophic}) - P_{device}}{P_{device}} \times 100\%$$

Unit Cost:

$$C_{unit} = \frac{C_{fixed, annual}}{V_{reports}} + C_{variable}$$

Value Share Pricing:

$$P_{value} = \alpha \times V_{total}$$

where $\alpha = 0.006-0.012$ (0.6-1.2% value capture)

Break-Even Volume:

$$V_{BE} = \frac{C_{fixed}}{P_{unit} - C_{variable}}$$

Per-Capita Conversion:

$$P_{capita} = P_{report} \times R_{average}$$

where $R_{average} = 7.5$ reports/patient/year